Abstract: The present invention provides a fused bicyclic compound according to formula (H) or a pharmaceutically acceptable salt thereof, wherein L is —S— or —O—; M is —CH?, —N? or —CJ=, wherein J is a non-hydrogen monovalent group; and W, G0 and G1 are independently of each other a non-hydrogen monovalent group. The invention further provides a pharmaceutical composition comprising the compound, a method of synthesizing the compound, a method for inhibiting CDK(s), a method for treating a disease or disorder in a mammal mediated by or associated with cyclin-dependent kinase (CDK), and a use of the compound in the manufacturing of a medicament for treating a CDK-mediated disease or disorder.